Ireland: Theravance Biopharma announces tender offer as part of Capital Return Programme

Nasdaq-listed Theravance Biopharma, has announced a “modified Dutch auction” tender offer to purchase up to US$95m of its ordinary shares, as set out in its US$250m Capital Return Programme, which earlier saw it execute a definitive agreement to purchase all of GSK’s equity stake, constituting approximately 9.6 million shares at US$9.75 per share. The company is offering to purchase…

You must be a HMI Subscriber to view this content.

Subscribe Now »